Medicus Pharma appoints Carolyn Bonner as CFO

Esme Needham | December 4, 2025 | Appointment | |  Medicus Pharma, chief financial officer 

Medicus Pharma has announced the appointment of Carolyn Bonner as Chief Financial Officer (CFO) in addition to her role as President.

Bonner has been serving as acting CFO since September 2025, providing leadership in the absence of former CFO Jim Quinlan, who has now resigned for health reasons. Bonner brings nearly two decades of experience across the healthcare and life sciences sectors. Prior to joining Medicus, she held the roles of President and CEO at specialty laboratory PCL. She has also held business and corporate development roles at Rosetta Genomics and Inform Diagnostics.

In her new combined role of President and CFO, Bonner will oversee Medicus’ budgeting and forecasting, financial reporting and controls, capital markets strategy and treasury operations. She will also continue to lead the planning and coordination of both clinical and corporate development initiatives.

Advertisement

“Carolyn has been providing strong financial leadership since stepping in as acting CFO in September,” Dr Raza Bokhari, executive chairman and CEO of Medicus, said. “Her appointment as CFO, in addition to President, enhances continuity, ensures stability and brings further alignment in our corporate objectives. These combined responsibilities also bring operational and financial integration under a single leader as Medicus advances its clinical development programmes and expands its clinical pipeline.”

Medicus is a biotechnology and life sciences company focused on the development of innovative therapies. It recently announced the acquisition of late clinical-stage biotechnology company Antev, as well as a strategic partnership with the Gorlin Syndrome Alliance and updates on trials of its SkinJect basal cell carcinoma treatment.

Related Content

Medicus Pharma shares updates on basal cell carcinoma trials

Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials …

The Gateway to Local Adoption Series

Latest content